A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Conditions: Hodgkin Lymphoma Interventions: Biological: JS004 in combination with Toripalimab; Drug: Bendamustine or gemcitabine Sponsors: Shanghai Junshi Bioscience Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials